JP2023535808A5 - - Google Patents
Info
- Publication number
- JP2023535808A5 JP2023535808A5 JP2023506111A JP2023506111A JP2023535808A5 JP 2023535808 A5 JP2023535808 A5 JP 2023535808A5 JP 2023506111 A JP2023506111 A JP 2023506111A JP 2023506111 A JP2023506111 A JP 2023506111A JP 2023535808 A5 JP2023535808 A5 JP 2023535808A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- gcase
- seq
- mutation
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2011813.9A GB202011813D0 (en) | 2020-07-29 | 2020-07-29 | Polypeptide |
| GB2011813.9 | 2020-07-29 | ||
| GBGB2100648.1A GB202100648D0 (en) | 2021-01-18 | 2021-01-18 | Polypeptide |
| GB2100648.1 | 2021-01-18 | ||
| GB2105924.1 | 2021-04-26 | ||
| GBGB2105924.1A GB202105924D0 (en) | 2021-04-26 | 2021-04-26 | Polypeptide |
| PCT/GB2021/051969 WO2022023761A2 (en) | 2020-07-29 | 2021-07-29 | Polypeptide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023535808A JP2023535808A (ja) | 2023-08-21 |
| JP2023535808A5 true JP2023535808A5 (enExample) | 2024-08-07 |
| JP7895925B2 JP7895925B2 (ja) | 2026-07-28 |
Family
ID=77265101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023506111A Active JP7895925B2 (ja) | 2020-07-29 | 2021-07-29 | 安定性の改善された変異型ベータ－グルコセレブロシダーゼ |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20240261433A1 (enExample) |
| EP (2) | EP4643868A3 (enExample) |
| JP (1) | JP7895925B2 (enExample) |
| KR (1) | KR20230042513A (enExample) |
| CN (1) | CN116322744A (enExample) |
| AU (2) | AU2021316875B2 (enExample) |
| BR (1) | BR112023001583A2 (enExample) |
| CA (1) | CA3189801A1 (enExample) |
| DK (1) | DK4118200T3 (enExample) |
| ES (1) | ES3057448T3 (enExample) |
| FI (1) | FI4118200T3 (enExample) |
| HR (1) | HRP20251591T1 (enExample) |
| IL (1) | IL299811A (enExample) |
| MX (1) | MX2023001137A (enExample) |
| PT (1) | PT4118200T (enExample) |
| WO (1) | WO2022023761A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024394235A1 (en) | 2023-12-08 | 2026-06-11 | Denali Therapeutics Inc. | Modified glucocerebrosidase polypeptides and methods of use thereof |
| WO2025166045A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF |
| CN118086341B (zh) * | 2024-04-25 | 2024-08-02 | 上海凌医生物科技有限公司 | 在肝脏中高表达人源葡萄糖脑苷脂酶基因的表达框 |
| TW202617982A (zh) | 2024-06-24 | 2026-05-01 | 美商戴納立製藥公司 | 包含經修飾之葡萄糖腦苷脂酶多肽之融合蛋白及其方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001036603A2 (en) * | 1999-11-17 | 2001-05-25 | Avigen, Inc. | Recombinant adeno-associated virus virions for the treatment of lysosomal disorders |
| IL150314A0 (en) * | 1999-12-30 | 2002-12-01 | Maxygen Aps | Improved lysosomal enzymes and lysosomal enzyme activators |
| CN104383556B (zh) | 2007-05-16 | 2018-06-05 | 布里格姆妇女医院 | 突触核蛋白病的治疗 |
| WO2011122950A1 (en) | 2010-04-01 | 2011-10-06 | Amsterdam Molecular Therapeutics (Amt) Ip B.V. | Monomeric duplex aav vectors |
| US8962564B2 (en) * | 2010-11-08 | 2015-02-24 | Amicus Therapeutics, Inc. | Variant, recombinant beta-glucocerebrosidase proteins with increased stability and increased retained catalytic activity |
| WO2013151664A1 (en) * | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of proteins |
| US9574184B2 (en) * | 2013-09-25 | 2017-02-21 | Children's Hospital Medical Center | Lysosomal protein targeting sequence and therapeutic applications of same |
| PE20181922A1 (es) * | 2016-04-15 | 2018-12-11 | Univ Pennsylvania | Terapia genica para tratar la hemofilia a |
| EP3692158A4 (en) | 2017-10-03 | 2021-08-04 | Prevail Therapeutics, Inc. | GENE THERAPIES FOR LYSOSOMAL DISEASES |
| CN111542549A (zh) | 2017-10-03 | 2020-08-14 | 普利维尔治疗公司 | 用于溶酶体障碍的基因疗法 |
| AU2019300431A1 (en) | 2018-07-13 | 2021-01-14 | Ucl Business Ltd | Glucocerebrosidase gene therapy |
| WO2020157248A1 (en) * | 2019-02-01 | 2020-08-06 | Oxyrane Uk Ltd | Glucocerebrosidase polypeptides |
-
2021
- 2021-07-29 KR KR1020237007296A patent/KR20230042513A/ko active Pending
- 2021-07-29 BR BR112023001583A patent/BR112023001583A2/pt unknown
- 2021-07-29 CN CN202180066422.7A patent/CN116322744A/zh active Pending
- 2021-07-29 IL IL299811A patent/IL299811A/en unknown
- 2021-07-29 US US18/017,158 patent/US20240261433A1/en active Pending
- 2021-07-29 FI FIEP21752123.6T patent/FI4118200T3/fi active
- 2021-07-29 WO PCT/GB2021/051969 patent/WO2022023761A2/en not_active Ceased
- 2021-07-29 MX MX2023001137A patent/MX2023001137A/es unknown
- 2021-07-29 EP EP25199900.9A patent/EP4643868A3/en active Pending
- 2021-07-29 EP EP21752123.6A patent/EP4118200B1/en active Active
- 2021-07-29 ES ES21752123T patent/ES3057448T3/es active Active
- 2021-07-29 DK DK21752123.6T patent/DK4118200T3/da active
- 2021-07-29 PT PT217521236T patent/PT4118200T/pt unknown
- 2021-07-29 CA CA3189801A patent/CA3189801A1/en active Pending
- 2021-07-29 HR HRP20251591TT patent/HRP20251591T1/hr unknown
- 2021-07-29 AU AU2021316875A patent/AU2021316875B2/en active Active
- 2021-07-29 JP JP2023506111A patent/JP7895925B2/ja active Active
-
2026
- 2026-06-30 AU AU2026205139A patent/AU2026205139A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7776477B2 (ja) | 転写調節要素及びその使用 | |
| CN111902539B (zh) | 杂合调控元件 | |
| KR102057540B1 (ko) | 세포, 기관 및 조직으로의 유전자 전이를 위한 ａａｖ 벡터 조성물 및 방법 | |
| KR102298579B1 (ko) | 캡시드-변형된 raav3 벡터 조성물, 및 인간 간암의 유전자 요법에서의 용도 | |
| CN116949052A (zh) | 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体 | |
| US10494619B2 (en) | High isomerohydrolase activity mutants of human RPE65 | |
| US20240091383A1 (en) | Synergistic effect of smn1 and mir-23a in treating spinal muscular atrophy | |
| CN104087591A (zh) | 用于基因治疗的修饰的因子viii和因子ix基因和载体 | |
| TW201629225A (zh) | 第九因子基因療法 | |
| EP3313991A1 (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| US20210403948A1 (en) | Liver-Specific Nucleic Acid Regulatory Elements and Methods and Use Thereof | |
| FI3850089T3 (fi) | Polynukleotidejä | |
| FI4118200T3 (fi) | Mutatoitu beetaglukoserebrosidaasi parannetulla stabiiliudella | |
| JP2022166181A (ja) | ヒト肝臓への遺伝子導入のためのアデノ随伴ウイルスビリオン | |
| US20170065685A1 (en) | Serca2 therapeutic compositions and methods of use | |
| CN110072593A (zh) | 适用于肾癌治疗的方法和药物组合物 | |
| US20240335506A1 (en) | Aqp1 gene therapy to prevent radiation induced salivary hypofunction | |
| US20240076691A1 (en) | Codon-optimized nucleic acid encoding the fix protein | |
| JP2022506174A (ja) | 改変第ｉｘ因子ポリペプチド | |
| RU2831751C2 (ru) | Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови IX, и ее применение | |
| OA21369A (en) | Codon-optimized nucleic acid encoding the fix protein. | |
| KR20250143161A (ko) | 시누클레인병증의 치료를 위한 유전자 요법 | |
| HK40109258A (en) | Codon-optimized nucleic acid encoding the fix protein | |
| RU2021105703A (ru) | Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови IX, и ее применение | |
| EA048549B1 (ru) | Кодон-оптимизированная нуклеиновая кислота, которая кодирует белок фактора свёртывания крови ix, и ее применение |